Quest for the right Drug
אווקסים 160 U AVAXIM 160 U (HEPATITIS A VACCINES)
תרופה במרשם
תרופה בסל
נרקוטיקה
ציטוטוקסיקה
צורת מתן:
תוך-שרירי : I.M
צורת מינון:
תרחיף להזרקה : SUSPENSION FOR INJECTION
עלון לרופא
מינוניםPosology התוויות
Indications תופעות לוואי
Adverse reactions התוויות נגד
Contraindications אינטראקציות
Interactions מינון יתר
Overdose הריון/הנקה
Pregnancy & Lactation אוכלוסיות מיוחדות
Special populations תכונות פרמקולוגיות
Pharmacological properties מידע רוקחי
Pharmaceutical particulars אזהרת שימוש
Special Warning עלון לרופא
Physicians Leaflet
Adverse reactions : תופעות לוואי
4.8. Undesirable effects Adverse event data are derived from clinical trials and worldwide post- marketing experience. Within each system organ class, the adverse events are ranked under headings of frequency, most frequent reactions first, using the following convention: Very common (≥1/10), Common (≥1/100, <1/10), Uncommon (≥1/1000, <1/100), Rare (≥1/10000, <1/1000), Very rare (<1/10000). Clinical Studies In clinical trials, adverse reactions were usually mild and confined to the first few days after vaccination with spontaneous recovery. The adverse reactions observed with AVAXIM 160 U were: Nervous system disorders Common: headache Gastrointestinal disorders Common: nausea, vomiting, decreased appetite, diarrhoea, abdominal pain Musculoskeletal and connective tissue disorders Common: myalgia/arthralgia General disorders and administration site conditions Very common: asthenia, mild injection site pain Common: mild fever Uncommon: injection site erythema Rare: injection site nodule Investigations Rare: transaminases increased (mild and reversible) Reactions were less frequently reported after the booster dose than after the first dose. In subjects seropositive against hepatitis A virus, AVAXIM 160 U was as well tolerated as in seronegative subjects. Post marketing experience Based on spontaneous reporting, the following additional adverse events have been reported during the commercial use of AVAXIM. These events have been very rarely reported, however exact incidence rates are not known (cannot be estimated from the available data). Nervous system disorders Vasovagal syncope in response to injection Skin and subcutaneous tissue disorders Urticaria, rashes associated or not with pruritus Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Any suspected adverse events should be reported to the Ministry of Health (www.health.gov.il) according to the National Regulation by using an online form https://sideeffects.health.gov.il
שימוש לפי פנקס קופ''ח כללית 1994
לא צוין
תאריך הכללה מקורי בסל
לא צוין
הגבלות
לא צוין
מידע נוסף
עלון מידע לרופא
12.08.20 - עלון לרופאעלון מידע לצרכן
12.08.20 - החמרה לעלוןלתרופה במאגר משרד הבריאות
אווקסים 160 U